Wessel Ganzevoort

Wessel Ganzevoort

Auto-generated profile, based on publicly available information

Wessel Ganzevoort

Department of Obstetrics and Gynaecology Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
Asma KhalilAsma Khalil
Asma Khalil
IBIrene Beune
Irene Beune
KHKurt Hecher
Kurt Hecher
KWKlaske Wynia
Klaske Wynia
WGWessel Ganzevoort
Wessel Ganzevoort
SGSanne J. Gordijn
Sanne J. Gordijn

1 May 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
MOMiriam F. van Oostwaard
Miriam F. van Oostwaard
JLJosje Langenveld
Josje Langenveld
ESEwoud Schuit
Ewoud Schuit
DPDimitri N.M. Papatsonis
Dimitri N.M. Papatsonis
MBMark A. Brown
Mark A. Brown
WGWessel Ganzevoort
Wessel Ganzevoort
We performed an individual participant data (IPD) metaanalysis to calculate the recurrence risk of hypertensive disorders of pregnancy (HDP) and recurrence of individual hypertensive syndromes. We performed an electronic literature search for cohort studies that reported on women experiencing HDP and who had a subsequent pregnancy. The principal investigators were contacted and informed of our study; we requested their original study data. The data were merged to form one combined database. The results will be presented as percentages with 95% confidence interval (CI) and odds ratios with 95% CI. Of 94 eligible cohort studies, we obtained IPD of 22 studies, including a total of 99,415 women. Pooled data of 64 studies that used published data (IPD where available) showed a recurrence rate of 18.1% (n=152,213; 95% CI, 17.9-18.3%). In the 22 studies that are included in our IPD, the recurrence rate of a HDP was 20.7% (95% CI, 20.4-20.9%). Recurrence manifested as preeclampsia in 13.8% of the studies (95% CI,13.6-14.1%), gestational hypertension in 8.6% of the studies (95% CI, 8.4-8.8%) and hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome in 0.2% of the studies (95% CI, 0.16-0.25%). The delivery of a small-for-gestational-age child accompanied the recurrent HDP in 3.4% of the studies (95% CI, 3.2-3.6%). Concomitant HELLP syndrome or delivery of a small-for-gestational-age child increased the risk of recurrence of HDP. Recurrence increased with decreasing gestational age at delivery in the index pregnancy. If the HDP recurred, in general it was milder, regarding maximum diastolic blood pressure, proteinuria, the use of oral antihypertensive and anticonvulsive medication, the delivery of a small-for-gestational-age child, premature delivery, and perinatal death. Normotensive women experienced chronic hypertension after pregnancy more often after experiencing recurrence (odds ratio, 3.7; 95% CI, 2.3-6.1). Among women that experience hypertension in pregnancy, the recurrence rate in a next pregnancy is relatively low, and the course of disease is milder for most women with recurrent disease. These reassuring data should be used for shared decision-making in women who consider a new pregnancy after a pregnancy that was complicated by hypertension.

1 May 2017 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
ABAnouk Bokslag
Anouk Bokslag
PTPim W. Teunissen
Pim W. Teunissen
CFConstantijn Franssen
Constantijn Franssen
FKFloortje van Kesteren
Floortje van Kesteren
OKOtto Kamp
Otto Kamp
CGChristianne J.M. de Groot
Christianne J.M. de Groot

1 June 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
APAnouk Pels
Anouk Pels
JDJan Derks
Jan Derks
AEAyten Elvan-Taspinar
Ayten Elvan-Taspinar
JDJoris van Drongelen
Joris van Drongelen
MBMarjon de Boer
Marjon de Boer
DGDutch STRIDER Trial Group
Dutch STRIDER Trial Group
Importance: Severe early onset fetal growth restriction caused by placental dysfunction leads to high rates of perinatal mortality and neonatal morbidity. The phosphodiesterase 5 inhibitor, sildenafil, inhibits cyclic guanosine monophosphate hydrolysis, thereby activating the effects of nitric oxide, and might improve uteroplacental function and subsequent perinatal outcomes.Objective: To determine whether sildenafil reduces perinatal mortality or major morbidity.Design, Setting, and Participants: This placebo-controlled randomized clinical trial was conducted at 10 tertiary referral centers and 1 general hospital in the Netherlands from January 20, 2015, to July 16, 2018. Participants included pregnant women between 20 and 30 weeks of gestation with severe fetal growth restriction, defined as fetal abdominal circumference below the third percentile or estimated fetal weight below the fifth percentile combined with Dopplers measurements outside reference ranges or a maternal hypertensive disorder. The trial was stopped early owing to safety concerns on July 19, 2018, whereas benefit on the primary outcome was unlikely. Data were analyzed from January 20, 2015, to January 18, 2019. The prespecified primary analysis was an intention-to-treat analysis including all randomized participants.Interventions: Participants were randomized to sildenafil, 25 mg, 3 times a day vs placebo.Main Outcomes and Measures: The primary outcome was a composite of perinatal mortality or major neonatal morbidity until hospital discharge.Results: Out of 360 planned participants, a total of 216 pregnant women were included, with 108 women randomized to sildenafil (median gestational age at randomization, 24 weeks 5 days [interquartile range, 23 weeks 3 days to 25 weeks 5 days]; mean [SD] estimated fetal weight, 458 [160] g) and 108 women randomized to placebo (median gestational age, 25 weeks 0 days [interquartile range, 22 weeks 5 days to 26 weeks 3 days]; mean [SD] estimated fetal weight, 464 [186] g). In July 2018, the trial was halted owing to concerns that sildenafil may cause neonatal pulmonary hypertension, whereas benefit on the primary outcome was unlikely. The primary outcome, perinatal mortality or major neonatal morbidity, occurred in the offspring of 65 participants (60.2%) allocated to sildenafil vs 58 participants (54.2%) allocated to placebo (relative risk, 1.11; 95% CI, 0.88-1.40; P = .38). Pulmonary hypertension, a predefined outcome important for monitoring safety, occurred in 16 neonates (18.8%) in the sildenafil group vs 4 neonates (5.1%) in the placebo group (relative risk, 3.67; 95% CI, 1.28-10.51; P = .008).Conclusions and Relevance: These findings suggest that antenatal maternal sildenafil administration for severe early onset fetal growth restriction did not reduce the risk of perinatal mortality or major neonatal morbidity. The results suggest that sildenafil may increase the risk of neonatal pulmonary hypertension.Trial Registration: ClinicalTrials.gov Identifier: NCT02277132

11 March 2014 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
WGWessel Ganzevoort
Wessel Ganzevoort
ZAZarko Alfirevic
Zarko Alfirevic
PDPeter von Dadelszen
Peter von Dadelszen
LKLouise Kenny
Louise Kenny
APAris Papageorghiou
Aris Papageorghiou
PBPhilip N Baker
Philip N Baker
In pregnancies complicated by early-onset extreme fetal growth restriction, there is a high risk of preterm birth and an overall dismal fetal prognosis. Sildenafil has been suggested to improve this prognosis. The first aim of this review is to assess whether sildenafil benefits or harms these babies. The second aim is to analyse if these effects are modified in a clinically meaningful way by factors related to the women or the trial protocol. The STRIDER (Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction) Individual Participant Data (IPD) Study Group will conduct a prospective IPD and aggregate data systematic review with meta-analysis and trial sequential analysis. The STRIDER IPD Study Group started trial planning and funding applications in 2012. Three trials will be launched in 2014, recruiting for three years. Further trials are planned to commence in 2015. The primary outcome for babies is being alive at term gestation without evidence of serious adverse neonatal outcome. The latter is defined as severe central nervous system injury (severe intraventricular haemorrhage (grade 3 and 4) or cystic periventricular leukomalacia, demonstrated by ultrasound and/or magnetic resonance imaging) or other severe morbidity (bronchopulmonary dysplasia, retinopathy of prematurity requiring treatment, or necrotising enterocolitis requiring surgery). The secondary outcomes are improved fetal growth velocity assessed by ultrasound abdominal circumference measurements, gestational age and birth weight (centile) at delivery, and age-adequate performance on the two-year Bayley scales of infant and toddler development-III (composite cognitive score and composite motor score). Subgroup and sensitivity analyses in the IPD meta-analysis include assessment of the influence of several patient characteristics: an abnormal or normal serum level of placental growth factor, absent/reversed umbilical arterial end diastolic flow at commencement of treatment, and other patient characteristics available at baseline such as gestational age and estimated fetal weight. The secondary outcomes for mothers include co-incidence and severity of the maternal syndrome of pre-eclampsia, mortality, and other serious adverse events. Trials are expected to start in 2013–2014 and end in 2016–2017. Data analyses of individual trials are expected to finish in 2019. Given the pre-planned and agreed IPD protocol, these results should be available in 2020.

1 August 2006 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
WGWessel Ganzevoort
Wessel Ganzevoort
ARAnnelies Rep
Annelies Rep
JVJohanna I.P. de Vries
Johanna I.P. de Vries
GBGouke J. Bonsel
Gouke J. Bonsel
HWHans Wolf
Hans Wolf